Immunity and protection by live attenuated HIV/SIV vaccines

Virology

Volumn 378, Issue 2, 2008, Pages 299-305

  Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dynamics; HIV; Live attenuated; Mathematical model; Protection; Theoretical biology; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MIXED INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED;

HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 49049105133     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.05.017     Document Type: Article

References (44)

1. Almond N., Kent K., Cranage M., Rud E., Clarke B., and Stott E.J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345 8961 (1995) 1342-1344
2. Altes H.K., and Jansen V.A. Intra-host competition between nef-defective escape mutants and wild-type human immunodeficiency virus type 1. Proc. Biol. Sci. 267 1439 (2000) 183-189
3. Asquith B., Edwards C.T., Lipsitch M., and McLean A.R. Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol. 4 4 (2006) e90
4. Bagnoli F., Lio P., and Sguanci L. Modeling viral coevolution: HIV multi-clonal persistence and competition dynamics. Physica, A 366 (2006) 333-346
5. Ball C.L., Gilchrist M.A., and Coombs D. Modeling within-host evolution of HIV: mutation, competition and strain replacement. Bull. Math. Biol. 69 7 (2007) 2361-2385
6. Bonhoeffer S., and Nowak M.A. Can live attenuated virus work as post-exposure treatment?. Immunol. Today 16 3 (1995) 131-135
7. Chen J., Dang Q., Unutmaz D., Pathak V.K., Maldarelli F., Powell D., and Hu W.S. Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor. J. Virol. 79 7 (2005) 4140-4149
8. Dang Q., Chen J., Unutmaz D., Coffin J.M., Pathak V.K., Powell D., KewalRamani V.N., Maldarelli F., and Hu W.S. Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc. Natl. Acad. Sci. U. S. A. 101 2 (2004) 632-637
9. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., and Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 5090 (1992) 1938-1941
10. De Boer R.J., and Perelson A.S. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 190 3 (1998) 201-214
11. Dixit N.M., and Perelson A.S. HIV dynamics with multiple infections of target cells. Proc. Natl. Acad. Sci. U. S. A. 102 23 (2005) 8198-8203
12. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., Oxenius A., Price D.A., Connors M., and Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 6884 (2002) 95-98
13. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin. Infect Dis. 43 4 (2006) 500-511
14. Gauduin M.C., Glickman R.L., Means R., and Johnson R.P. Inhibition of simian immunodeficiency virus, (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV. J. Virol. 72 8 (1998) 6315-6324
15. Hofmann-Lehmann R., Vlasak J., Williams A.L., Chenine A.L., McClure H.M., Anderson D.C., O'Neil S., and Ruprecht R.M. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. Aids 17 2 (2003) 157-166
16. Johnson R.P., and Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10 4 (1998) 436-443
17. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Montefiori D.C., Montelaro R., Wyand M.S., and Desrosiers R.C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73 6 (1999) 4952-4961
18. Jung A., Maier R., Vartanian J.P., Bocharov G., Jung V., Fischer U., Meese E., Wain-Hobson S., and Meyerhans A. Multiply infected spleen cells in HIV patients. Nature 418 6894 (2002) 144
19. Klausner R.D., Fauci A.S., Corey L., Nabel G.J., Gayle H., Berkley S., Haynes B.F., Baltimore D., Collins C., Douglas R.G., Esparza J., Francis D.P., Ganguly N.K., Gerberding J.L., Johnston M.I., Kazatchkine M.D., McMichael A.J., Makgoba M.W., Pantaleo G., Piot P., Shao Y., Tramont E., Varmus H., and Wasserheit J.N. Medicine. The need for a global HIV vaccine enterprise. Science 300 5628 (2003) 2036-2039
20. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., and Desrosiers R.C. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 7 1 (2006) 19-23
21. Letvin N.L. Progress in the development of an HIV-1 vaccine. Science 280 5371 (1998) 1875-1880
22. Levy D.N., Aldrovandi G.M., Kutsch O., and Shaw G.M. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. U. S. A. 101 12 (2004) 4204-4209
23. Lifson J.D., Rossio J.L., Arnaout R., Li L., Parks T.L., Schneider D.M., Kiser R.F., Coalter V.J., Walsh G., Imming R., Fischer B., Flynn B.M., Nowak M.A., and Wodarz D. Containment of SIV infection: cellular immune responses and protection from rechallenge following transient post-inoculation antiretroviral treatment. J. Virol. 74 (2000) 2584-2593
24. Lifson J.D., Piatak Jr. M., Cline A.N., Rossio J.L., Purcell J., Pandrea I., Bischofberger N., Blanchard J., and Veazey R.S. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J. Med. Primatol. 32 4-5 (2003) 201-210
25. Mansfield K., Lang S.M., Gauduin M.C., Sanford H.B., Lifson J.D., Johnson R.P., and Desrosiers R.C. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol. 82 8 (2008) 4135-4148
26. Marthas M.L., Miller C.J., Sutjipto S., Higgins J., Torten J., Lohman B.L., Unger R.E., Ramos R.A., Kiyono H., McGhee J.R., et al. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J. Med. Primatol. 21 2-3 (1992) 99-107
27. Metzner K.J., Jin X., Lee F.V., Gettie A., Bauer D.E., Di Mascio M., Perelson A.S., Marx P.A., Ho D.D., Kostrikis L.G., and Connor R.I. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 191 11 (2000) 1921-1931
28. Nowak M.A., and Bangham C.R. Population dynamics of immune responses to persistent viruses. Science 272 5258 (1996) 74-79
29. Nowak M.A., and May R.M. Virus dynamics. Mathematical principles of immunology and virology (2000), Oxford University Press
30. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev., Immunol. 2 1 (2002) 28-36
31. Ruprecht R.M. Live attenuated AIDS viruses as vaccines: promise or peril?. Immunol. Rev. 170 (1999) 135-149
32. Ruprecht R.M., Baba T.W., Li A., Ayehunie S., Hu Y., Liska V., Rasmussen R., and Sharma P.L. Live attenuated HIV as a vaccine for AIDS: pros and cons. Semin. Virol. 7 (1996) 147-155
33. Smith R.J., and Wahl L.M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 67 4 (2005) 783-813
34. Stahl-Hennig C., Eisenblatter M., Franz M., Stoiber H., Tenner-Racz K., Suh Y.S., Jasny E., Falkensammer B., Ugucchioni M., Georgsson G., Baroni C., Dierich M.P., Lifson J.D., Steinman R.M., Uberla K., Racz P., and Ignatius R. A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum. Front Biosci. 12 (2007) 2107-2123
35. Stebbings R., Berry N., Stott J., Hull R., Walker B., Lines J., Elsley W., Brown S., Wade-Evans A., Davis G., Cowie J., Sethi M., and Almond N. Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 330 1 (2004) 249-260
36. Stebbings R., Berry N., Waldmann H., Bird P., Hale G., Stott J., North D., Hull R., Hall J., Lines J., Brown S., D'Arcy N., Davis L., Elsley W., Edwards C., Ferguson D., Allen J., and Almond N. CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J. Virol. 79 19 (2005) 12264-12272
37. Stebbings R., Stott J., Almond N., Hull R., Lines J., Silvera P., Sangster R., Corcoran T., Rose J., Cobbold S., Gotch F., McMichael A., and Walker B. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res. Hum. Retrovir 14 13 (1998) 1187-1198
38. Whitney J.B., and Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect Dis. 17 1 (2004) 17-26
39. Wodarz D. Killer Cell Dynamics: mathematical and computational approaches to immunology (2007), Springer, New York
40. Wodarz D., and Krakauer D.C. Defining CTL-induced pathology: implications for HIV. Virology 274 1 (2000) 94-104
41. Wodarz D., and Levy D.N. Human immunodeficiency virus evolution towards reduced replicative fitness in vivo and the development of AIDS. Proc. Biol. Sci. 274 1624 (2007) 2481-2490
42. Wodarz D., Lloyd A.L., Jansen V.A.A., and Nowak M.A. Dynamics of macrophage and T cell infection by HIV. J. Theor. Biol. 196 (1999) 101-113
43. Wodarz D., Arnaout R.A., Nowak M.A., and Lifson J.D. Transient antiretroviral treatment during acute SIV infection facilitates long-term control of the virus. Phil. Trans. Roy. Soc. Lond. B 355 (2000) 1021-1029
44. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., and Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73 10 (1999) 8356-8363